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U r-..'TIL about 2 years ago. a transplanted organ was 
seen as an island in a hostile recipient sea. Then. a 
different perspective emerged about the reason for organ 
graft acceptance. I This was based on the startling observa-
tion that donor leukocytes from these transplanted organs 
had migrated and survived throughout the body of the 
recipient for as long as three decades. 2- 6 The events 
following transplantation then were seen as a two-way cell 
interaction-one direction being a graft-vs-host reaction 
and the other the conventional host-vs-graft (rejection) 
reaction. 
Because the so-called passenger leukocytes from the 
graft were multilineage and derived originally from the 
bone marrow. the organ transplantation was in effect a mini 
bone marrow transplantation. At tbe vast interface between 
the coexisting donor and recipient cell populations. we 
suggested that changes occurred in the way each cell 
population viewed the other. and that these changes de-
fined the mysterious suppressor and veto cells about which 
hundreds of articles have been written.1.6 
We believe that the liver is the most tolerogenic trans-
planted organ because of its much larger total load as well 
as its lineage profile of the migratory leukocytes. With the 
liver and other leukocyte-rich organs. the duality of the 
immunologic reactions-graft-vs-host and host-vs-graft-
were thought to be especially important.5 However. with all 
successful transplantations. no matter what the organ. the 
graft as well as the recipient became genetic composites 
following the migration. composed of cells of both parties. 
This transition within the graft is particularly dramatic in 
the successfully transplanted intestine in which the donor 
epithelium sits on a bed of leukocytes that can be identified 
as recipient with specific monoclonal antibodies. 7•H The 
presence of a double cell population also is dramatically 
evident in the Iiver"·II) and less so in kidney I I and heart. 
No matter what organ is transplanted. there are. of 
course. David and Goliath proportions of the donor and 
recipient cell populations at the outset. but in each. the 
intcraction of the two cell populations can be envisioned as 
a to:eter·tottcr in which each side can cancel the immuno-
logic effect of the other in what we have called mutual 
natural immunosuppression. We believe that this reciprocal 
interaction blindfolds the MHC effect and explains very well 
why tissue matching. which is crucial for successful clinical 
bone marrow transplantation. does not accurately predict 
outcome after transplantation of whole organsKl~ 
In our original description of the spontaneous chimerism. 
we emphasized that graft acceptance by this mechanism 
may "become stable without further treatment. or (in other 
cases) only when continued immunosuppression is provid-
ed."1 Failure was defined as instability of the chimerism 
which could be manifested by rejection (most commonly), 
but also by graft-vs-host disease (GVHD). Although organ 
acceptance was different than the acquired tolerance of 
Billingham et al,13.14 the relation of the two was easy to 
understand. 
The experimental model of Billingham et al was unbal-
anced by reason of recipient immunologic immaturity. 
Imbalance can also be achieved genetically in the F 1 hybrid 
parent-to-offspring animal model, and iatrogenically by 
recipient cytoablation with irradiation or cytotoxic drugs. 
Then, if the immunocytes in the transplanted organ are 
sufficiently numerous (as in the intestine), one of the 
censoring limbs is absent and GVHD follows in the same 
way as with bone marrow transplantation (Fig 1). However, 
if neither the recipient nor the graft is leukocyte depleted. 
it is possible to routinely perform intestinal or even multi-
visceral transplantation without an exorbitant risk of graft-
vs-host disease. 15 
The natural chimerism concept defines the difference 
between bone marrow and whole organ transplantation 
entirely in terms of the therapeutic strategies that are used. 
Bone marrow transplantation is conceptually derived di-
rectly from the original Billingham et al model in that one 
of the immunologic reaction limbs is iatrogenically disabled. 
This leaves the recipient GVHD prone. and requires MHC 
matching for survival. Success is called tolerance. In con-
trast. the treatment strategy evolved empirically for whole 
organ transplantation leaves both cell populations intact. 
thereby removing MHC matching as a requisite for success. 
and largely eliminates the threat of GVHD. Engraftment of 
the transplanted organ. which depends on survival of the 
donor leukocyte population. commonly is called graft ac-
ceptance. 
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ALL NATURE IS BUT ART UNKNOWN TO THEE" 
Two important clues that cell migration or something like it 
must be occurring were observed in the first patients to be 
treated with the combination of azathioprine and pred-
nisone. Rejection could be easily reversed in these kidney 
recipients. and more importantly, there was a subsequent 
ability to lighten immunosuppressive doses. often to sur-
prisingly low levels. 16 This was referred to in the title of the 
article as tolerance. Although the term was bitterly criti-
cized at the time. it has proved to be conceptually ~orrect 
(see later). The implication was not that drugs could be 
stopped but that the evolution of donor-specific nonreac-
tivity had begun. 
The use of living volunteer kidney donors for these 
pioneer patients made their prototype course easy to char-
acterize. After a few days or weeks of good function of the 
transplanted kidney. the initially high creatinine clearance 
and satisfactorily low BUN obtained in most cases deteri-
orated with the onset of a rejection. These adverse events 
• All Nature IS but Art unknown to thee; 
All Chance direction which thou cans't not see; 
All Discord Harmony not understood; 
All partial Evil universal Good. 
And spite 01 Pride, in erring Reason's spite, 
One truth is clear, "Whatever IS, is RIGHT." 
Alexander Pope (Essay on Man): 1730 A.D. 
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Fig 1. Transplantation 01 a leu-
kocyte-rich organ (eg, small 
bowel) into a recipient who has 
been cytoablated with irradia-
tion or cytotOXiC drugs, or else 
into a F 1 hybrid parent-to-of!-
spnng animal will lead to graft-
vs-host-disease (GVH) but will 
not initiate host-vs-gratt reac-
tions (HVG). 
were easily reversed with what were then thought to be 
astronomical doses of prednisone. More importantly, the 
steroids could be weaned or in some cases stopped, and 
usually the eventual azathioprine dose was lowered to less 
than what had failed at the outset to prevent rejection of 
variable severity. A number of these patients then had 
stable graft function for more than 30 years. 17 
These observations crystallized the central therapeutic 
dogma upon which whole organ transplantation is based. It 
calls for baseline therapy with one or two drugs, secondary . 
adjustments as needed with steroids. and then individual-
ized drug weaning to whatever maintenance levels are 
required to have stable graft function. The baseline agents 
have improved through the years (Table I), but the dogma 
has remained the same. 
In the ensuing three decades. many details of rejection 
were clarified: its dependence on antigen-presenting cells. 
the necessity for a costimulatory molecule. the role of 
accessory molecules, and the way that cytokines controlled 
clonal expansion of T helper and the cytotoxic T cells that 
are the agents of allograft destruction. However. the curi-
ous thing. which has been most completely documented in 
experimental animals. was the diversity of agents with which 
long-term or permanent graft survival could be induced 
with a short course of therapy no matter what the level of 
intervention in the immune reaction. IM Deoxyspergualin 
was said to alter the antigen-presenting cell. The antime-
tabolites prevented clonal expansion by inhibition of DNA 
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Table 1. Central Therapeutic Dogma of Immunosuppression 
Strategy 
Baseline therapy with one or two drugs 
Secondary adjustments with steroids or anti/ymphoid agents 
Case by case trial (and potential error) of weaning 
synthesis. Cyclosporine (CyA) and FK 506 disrupted T-cell 
receptor signals to the nucleus. Monoclonal antibodies 
interrupted the immune reaction at various specific targets. 
including accessory molecules, and rapamycin interdicted 
the action of normally formed cytokines. These nonspecific 
drugs appeared to be permissive of a natural event that 
became specific only by virtue of the presence of donor 
antigens. 
What was happening was revealed in retrospect by stud-
ies nearly 30 years posttransplantation of a group of pa-
tients treated at the University of Colorado in 1962 and 
1963 with the then new azathioprine-prednisone protocol. 
Both the donors and recipients underwent preoperative 
delayed hypersensitivity skin tests with tuberculin, his-
toplasmin. and other antigens. Recipients who were nega-
tive to these antigens preoperatively but whose donors were 
positive acquired the positive skin tests if the kidney 
transplantation succeeded. but not if it failed. The explana-
tion offered was adoptive transfer of immunity. which 
explicitly meant the migration of donor leukocytes. I'> How-
ever. this was not considered plausible because the kidney 
at that time was thought to be a leukocyte-poor organ. 
However. the memory of the earlier observations lin-
gered on. and in the spring and summer of 1992. five of 
these original patients whose grafts still functioned nor-
mally were studied for chimerism in their blood. skin. and 
Ivmph nodes. Their donors. who still were alive. cooper-
ated. All nve recipients were found to be chimerasK~ The 
identity of the donor and recipient cells was established 
with either cytostaimng. allowing the donor cells to be seen 
in the tissues. or by polymerase chain reaction (PCR). 
which identified donor DNA. The markers were donor-
specific HLA alleles of chromosome 6 and the Y chromo-
some when there had been a male donor to female recipi-
ent. 
Chimerism also was found in all 22 liver recipients who 
were studied from 10-1/2 to 21 years after liver replace-
ment. Its generalized nature was evident from a more 
complete tissue sampling than in the kidney reCipients.' In 
addition to possessing donor HLA. alleles in the chimeric 
cells. nIne of these hepatic recipients were women who had 
heen given male livers. The chimerism was confirmed in all 
nine cases by the additional presence of Y chromosomes. 2 
The identifiable chimeric cells usuallv were sparse. esti-
mated to be I tlOOO or fewer. However. confirmatory PCR 
studies in all of the kidney and liver recipients left no doubt 
ahout the validity of the cytochemical findings. 
Baseline Agents 
Azathioprine 
Cyclophosphamide 
CyA 
FK 506 
Mode of Action 
DNA synthesis 
DNA synthesis 
IL-2 production 
IL-2 production 
Before long. chimerism also was proved in recipients of 
thoracic organs.' An important study was reported last 
week in Venice by the Pittsburgh group who stratified 15 
lung transplant recipients followed I to 5 years into a 
favorable group of 8 with no bronchiolitis obliterans and 7 
who had the ominous finding of chronic rejection. The 
patients without bronchiolitis obliterans had dense chimer-
ism-positive in seven of seven lymph nodes. seven of eight 
skin biopsies. and six of eight blood samples. Chimerism 
was demonstrable in the less favored group, but less regu-
larly and with a generally lower quantitative grade. Using 
the cryopreserved donor spleen cells as stimulators. donor-
specific nonreactivity was demonstrated in all but one of the 
densely chimeric recipients, but in only one of the less 
favored group (Table 2). 
CAN DRUGS BE STOPPED? 
Uver Recipients 
Once it is conceded that organ graft acceptance is mecha-
nistically associated with the surviving donor multilineage 
passenger leukocytes. it is possible to envision the engraft-
ment of any whole organ in the same context as a small 
hone marrow transplantation. Then. the natural question is 
if some of these patients could have their immunosuppres-
sion stopped all together. At the time (in April-J une ) 992) 
of the chimerism investigations. there were 43 patients who 
had survived for 12 to 23 years after liver replacement. Six 
of them had long since discontinued therapy. to whom four 
more have been added. Presently. lO of the remaining 43 
long-term survivors have been drug free for 1 to 15 years. 
Because complications of immunusuppression have been 
the principal causes of late death in our chronically surviv-
ing liver recipient population. a prospective weaning trial 
Table 2. Donor Cell Chimerism and In Vitro Immune Reactivity; 
Correlation With Bronchiolitis Obliterans in Lung Allograft 
ReCipients 1-5 Years After Transplantation 
Donor Cell Chimerism 
MLR 
BronchiolitiS Lymph Donor·Speclfic 
Obliterans n Blood Sktn Node Hyporeactlvlty 
No 8 6/8 7/8 717 6!7' 
Yes 7 317 2/7 3/7 1/4 t 
From Keenan et al Isee text abOve). 
'One patient had persistently low pre· and posttransplant MLR responses. 
'In vitro Immune testing was only poSSible In five of seven reciPients: of the 
live tested. one had perSistently low pre· and posttransplant MLR responses 
(petfectly matched MHC class II). 
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was begun. Some patients were excluded for a variety of 
reasons, but a total of 59 were entered. Twenty-one already 
have had complete weaning from 3 months to 13 years. 
Twenty-four more have had reductions to homeopathic 
doses over 4 to 14 months. Immunosuppression has been 
resumed in only 24% of cases because of mild rejection in 
nine patients. moderate rejection in three, and histopatho-
logically severe rejection in two. No patients became jaun-
diced, no grafts were lost, and there was no permanent loss 
of graft function. The patients who flunked the trial were 
restored to preexisting immunosuppression. Our conclusion 
is that cautious weaning can be safely undertaken under 
careful surveillance 5 or 10 years after liver transplantation. 
Kidney Recipients 
Drug discontinuance is far more dangerous in kidney 
recipients. but it is well known to be feasible in isolated 
cases. Among 10 of our patients from 1962 to 1963. 
including a man bearing the longest continuously function-
ing kidney allograft in the world and about 2/3 of such 
survivors left from the world's experience preceding 1964. 17 
4 were MHC matched but the other 6 had one or two 
haplotype mismatches. When tested in 1992 along with 
their donors. all of these patients had donor-specifi~ non-
reactivity by mixed lymphocyte reaction (MLR) and cell-
mediated lympholysis (CML) testing, which was absolute in 
8 of the 10 cases and pronounced in the other 2. 
Five of these 10 patients are off immunosuppression and 
have been for 1. 1-2/3, 14,28, and 30 years. Three of the five 
drug-free patients did not have Hl.A identity and had been 
shown by detection of donor Hl.A alleles to have chimerism 
in their tissues. Thus, chimerism may be stable without 
further treatment, instead of requiring immunosuppression 
for lifetime as we have always assumed in the past. AJ-
though trying to predict which patients can come off drugs 
is an unpredictable ;md dangerous exercise, the fact that 
kidney recipients can achieve this state is the point to be 
made. 
IATROGENIC AUGMENTATION OF CHIMERISM 
If chimerism is a seminal event in graft acceptance, it would 
be advantageous to add to the minimal dose of the so-called 
passenger leukOcytes, which are of bone marrow origin (see 
earlier), by giving unaltered donor bone marrow at the time 
the natural chimerism occurs, namely perioperatively. Such 
a trial is well underway in Pittsburgh and now includes 30 
patients. 2o The donor bone marrow cells are obtained from 
the thoracico-lumbar vertebrae of the cadaveric donor. This 
is a rich source of leukOcytes that contains fewer mature T 
leukocytes than in other locations. 
The first 18 patients given 3 x lOx cells/kg included 7 liver 
recipients (1 also given pancreatic islets), 10 kidney recipi-
ents (2 with pancreatic islets), and 1 recipient of a heart. 
The patients were not preconditioned. and postoperative 
immunosuppression was with standard FK 506 and pred-
nisone. All 18 patients have had a very good clinical result. 
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Seventeen of the 18 patients have demonstrable macro-
chimerism. the only exception being a kidney recipient who 
had no markers to be studied because of a perfect MHC 
match with a donor of the same sex. The use of different 
technologies allowed cross-confirmation of results. The 
highest yield was with PCR. showing chimerism in 16 of the 
18 cases. Quantitation of the chimerism also was done with 
a technique of PCR coamplification developed by Dr 
Massimo Trucco and his associates. ~o After male-to-female 
transplantation in four cross-sex combinations. all four 
recipients had Y chromosomes detectable, and in these 
cases there was an excellent correlation with the results 
obtained using donor HLA allele detection. 
The yield with flow cytometry was 14/18. showing .9% to 
6.4% circulating donor leukocytes 3 months to 1 year after 
transplantation. After the marrow-organ transplantation, 
the initial wave of circulating donor cells usually recedes to 
a nadir after 2 or 3 months and then increases progressively 
to a stable level thereafter. The density of chimerism was 
estimated to be generally IOOOx or greater than that 
occurring spontaneously. The follow-up on these patients is 
now 4 to 16 months. 
Twelve of the 17 patients who could be studied have 
lower donor-specific reactivity by MLR to third party cells. 
and in 9 there was multiple other in vitro evidence of 
donor-specific nonreactivity. as early as 50 days following 
transplantation. The exceptional patient in the series who 
maintained vigorous donor-specific reactivity was the heart 
recipient who had two rejections. the first at 1 month and 
the second at 60 days. These were treated with OKTI 
and/or the addition of azathioprine. However. throughout 
the course, this patient always maintained blood chimerism. 
Circulating donor leukocytes were initially in the 10% 
range. and stabilized at 6% at the end of 160 days (Fig 2). 
Despite this high level of chimerism and a good clinical 
result, donor and third party-specific reactivity have re-
mained parallel. 
There have been no serious complications in this trial. 
now totalling 30 patients. As was expected. rejection has' 
been diagnosed in 50% of cases. but this was controlled with 
no more difficulty than usual. In two patients, a mild skin 
rash. which previously would have been passed off as a drug 
rash in a nonmarrow patient. was proved by biopsy to be 
minimal GVHD. These rashes. both in liver recipients. 
resolved spontaneously in one patient and in the other 
involuted after a minimal increase in her routine immuno-
suppression. 
With these results in hand. it is worth briefly reviewing 
earlier efforts to use donor leukOcytes to induce organ graft 
acceptance. The most extensive have been with the strategy 
developed by Monaco et al~1 in which donor bone marrow 
was stored and given about 3 weeks later by Barber et al of 
A1abama~~ to a large group of kidney recipients and by 
Rolles et al in England13 to liver recipients. The results 
were disappointing, particularly in the English liver trials. 
reported in The Lancet last January 15.2.3 Inexplicably. chi-
merism could not be found in the British patients. either in 
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Fig 2. Immunosuppression profile, serial in vitro donor (11), and 
third party (el specific MLR responses and the level of donor cell 
chimerism (as determined by flow cytometry) in a simultaneous 
heart and bone marrow transplant recipient. 
the control or bone marrow augmented recipients. With 
what we now know. the delayed timing of the bone marrow 
must he questioned. 
Donor-specific transfusion. such as advocated by Salva-
tierra et al.c", is another example of the leukocyte augmen-
tation principle. hut in these trials (especially those else-
where than in San Francisco). the timing was highly 
variahie-fr..:quently well before organ transplantation-
and often with no attention to preserving the white cells or 
even with their deliberate destruction or removal. 
SEARCH FOR THE TOLEROGENIC CELL 
The clinical portion of this discussion has been presented 
first hecause it provided the pathway of discovery. However. 
much additional information has been added. In immuno-
suppressed rats. Demetris et al c< have shown how the 
migratory cells begin to home to the central lymphoid 
organs within minutes. where their identification can be 
facilitated bv mjecting gamma interferon (to increase anti-
gen expression) a few hours before the animals are killed. eM 
After a pause of 2 or 3 weeks. the leukocytes break out and 
necome generalized. 
These studies and those in micee~ showed that the 
migratJon IS multilineage. following the same routes as 
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syngeneic cells-B cells to B-cell areas of the lymph nodes, 
spleen, and thymus. T cells to T-cell-rich regions, and the 
dendritic cells and macrophages to their normal destina-
tions. A bonus in the mouse experiments was the finding 
that permanent survival of liver allografts occurred without 
the need for treatment with all MHC disparities. These 
mouse liver recipients could accept donor strain skin and 
heart. but not grafts from third parry strains. The degree of 
natural chimerism was similar to that in rats. 
Having obtained so much suggestive evidence that chi-
merism is the fundamental explanation of graft acceptance. 
the obvious question was how the migratory leukocytes 
induced tolerance. To address the question, the mouse liver 
was chosen as the source of nonparenchymal leukocytes.28 
After separating the hepatocytes and duct cells from the 
leukocytes. about 1.0 x 107 nonparenchymal cells (NPCs) 
could be obtained from one mouse liver. Using the tech-
nique described by Inaba et al,29 these NPCs were cultured 
in granulocyte macrophage colony stimulating factor (GM-
CSF)-enriched medium, which gives a selective growth 
advantage to leukocytes of myeloid lineage. After 4 or 5 
days of culture, there was a subpopulation of approximately 
2 million cells which expressed cell surface markers char-
acteristic of dendritic cells (NLDC-145+, 33Dl +, and 
N418+). 
From the cluster of these cells that formed on the bottom 
of the liquid culture wells, cells that floated free were 
picked out for further culture and studied. These had the 
light and electron microscopic appearance of a precursor of 
dendritic cells. However, it was difficult at first to prove that 
they actually were dendritic cells because it was impossible 
to drive them to maturation, even after pulsing the culture 
with gamma interferon and tumor necrosis factor. They 
were not allostimulatory. could not be made to express high 
levels of class II antigen. and were avidly phagocytic. 
The impasse was broken after it was pointed out (A.J.D.) 
that the majority of dendritic cells in normal livers are 
located in the areas that are rich in type I collagen. When 
this microenvironment was simulated by coating the culture 
wells with type I collagen. the precursor cells promptly 
assumed the properties of dendritic cells. now strongly 
expressing class II antigen. However. it was still not known 
if these cells would mature and express class II antigen in 
vivo. This question was answered by injecting purified 
precursor cells (class II-depleted) from fully allogeneic 
B IO.BR livers into the footpad of B \0 mouse recipients. 
They migrated promptly to the T-cell areas of the central 
lymphoid organs where they were easily identified as donor 
with donor-specific monoclonal antibodv staining and 
shown to express class II antigen. 2' Thus. their character 
depended on the microenvironment in which they were 
placed. 
The crucial next step explains (we believe) how chimeric 
dendritic cells. \\ hich have been thought to have a life 
expectancy of only a few days or weeks. could be perpetu-
ated in the tissues of our patients for up 10 30 years. In the 
first phase of these mouse experiments. liver transplanta-
--
3076 
tion was carried out in the fully allogeneic but nonrejecting 
mouse strain (combination 81O-+C3H). As expected. the 
recipient animals became chimeric. Samples containing 
the mixed donor and recipient cells were collected from the 
spleen. thymus. and lymph nodes. In these tissues. donor as 
well as recipient dendritic cells at variable stages of matu-
ration could be demonstrated with the same culture tech-
niques as had been used for study of the liver cell popula-
tion (Lu. personal communication. March n. 19(4). Our 
assumption is that these cells were derived from precursor 
dendritic cells or even pluripotent stem cells in these widely 
distributed recipient foci. In the liver recipients. the profile 
of both donor and recipient cells was much the same 4. 14. 
or 150 days after the transplantation. 
Thus. the liver grafts had exported leukocytes that gen-
erated multiple active niduses that included donor as well as 
similar recipient precursor cells. The result was the creation 
of widespread and persistent cellular oasis. Even though 
heart grafts were rejected in similar but separate experi-
ments. they also initiated the same process. but apparently 
not vigorously or extensively enough for it to be self-
sustaining. These remarkable findings suggest a mechanism 
for perpetuation of the migratory dendritic cells. and along 
with an independent line of inquiry by Hara et aVo they 
have suggested a means by which the chimeric cells can be 
tolerogenic. 
Hara et al have shown that the anterior chamber of the 
eye, which is an immunologically privileged site, is lined by 
immature dendritic cells. In the anterior chamber, which 
Hara et al described as being rich in transforming growth 
factor beta (TGFfI), antigenic peptides are engulfed by 
these cells and travel to the spleen where they evoke a 
tolerogeneic instead of antigenic response. We suspect that 
our subpopulation of hepatic NPCs. smaller numbers of 
similar cells in other organs. and Hara et aI's tolerogenic 
anterior chamber cells are fundamentally the same. Verba-
nac et al:1' have obtained evidence that the veto cell is an 
immature dendritic cell whose function is TGFt3 linked. 
COMMENT 
It is hard to understand how at least the crude outlines of a 
phenomenon as obvious and fundamental as the spontane-
ous chimerism of this discussion could have escaped our 
notice for all these years. When clinical organ transplanta-
tion wa<; first performed on a large scale beginning in 1962, 
it was predicted to fail by most immunologists. Yet it 
succeeded. understandably to the special bewilderment of 
those who ostensibly knew the most. The reasons why it 
succeeded now seem to us self-evident. The clues were 
always there. in every clinic around the world. but they were 
ignored because they did not fit preconceived patterns. 
Having now seen both sides of the bidirectional cell reac-
tion that is implicit with cell migration and chimerism after 
whole organ transplantation, we have crawled intellectually 
inside of the system. We believe that this will allow us to 
improve the ways that we manage our patients. 
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